Filtered By:
Management: Marketing

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Umbilical Cord Blood Mononuclear Cells for Ex-Vivo Gene Therapy
This study was supported by the grant of Russian Science Foundation No 16-15-00010. Kazan Federal University was supported by the Russian Government Program of Competitive Growth.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Bashirov, F. V., Salafutdinov, I. I., Sokolov, M. E., Izmailov, A. A., Markosyan, V. A., Fadeev, F. O., Rizvanov, A., Islamov, R. I. Tags: 801. Gene Therapy and Transfer Source Type: research

Medtronic to pay $51m to settle Covidien, ev3 DoJ investigations
Medtronic (NYSE:MDT) said yesterday that it agreed to pay $50.9 million to settle a number of U.S. Dept. of Justice probes into marketing activities from companies it acquired, Covidien and ev3. Medtronic said that its subsidiary ev3, acquired when the Fridley, Minn.-based medtech giant picked up Covidien in 2015, agreed to plead guilty to a misdemeanor charge related to its marketing of the Onyx Liquid Embolic System, pay $17.9 million and adopt new compliance and reporting terms for three years. The charges relate to ev3’s marketing of the device for “unproven and potentially dangerous uses,” federal prose...
Source: Mass Device - December 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Legal News Medtronic Source Type: news

Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association.
The objectives of this statement are to describe the design and operation of water pipes and their use patterns, to identify harmful and potentially harmful constituents in water pipe smoke, to document the cardiovascular risks of water pipe use, to review current approaches to water pipe smoking cessation, and to offer guidance to healthcare providers for the identification and treatment of individuals who smoke tobacco using water pipes. PMID: 30845826 [PubMed - as supplied by publisher]
Source: Circulation - March 7, 2019 Category: Cardiology Authors: Bhatnagar A, Maziak W, Eissenberg T, Ward KD, Thurston G, King BA, Sutfin EL, Cobb CO, Griffiths M, Goldstein LB, Rezk-Hanna M, American Heart Association Behavioral Change for Improving Health Factors Committee of the Council on Lifestyle and Cardiometab Tags: Circulation Source Type: research

More Research Is Needed on Lifestyle Behaviors That Influence Progression of Parkinson's Disease
This article highlights some of these challenges in the design of lifestyle studies in PD, and suggests a more coordinated international effort is required, including ongoing longitudinal observational studies. In combination with pharmaceutical treatments, healthy lifestyle behaviors may slow the progression of PD, empower patients, and reduce disease burden. For optimal care of people with PD, it is important to close this gap in current knowledge and discover whether such associations exist. Introduction Parkinson's disease (PD) is an age-related complex progressive neurodegenerative disorder, with key p...
Source: Frontiers in Neurology - April 29, 2019 Category: Neurology Source Type: research

In Brief: Tegaserod (Zelnorm) Returns
Date: May 6, 2019 Issue #:  1571Summary:  Tegaserod maleate(Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults<65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic ...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Constipation irritable bowel syndrome Motegrity prucalopride Resotran Tegaserod Zelnorm Source Type: research

Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants
AbstractLarge-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants (DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since 2011 in Japan, and the results of the last one have recently been published. Each reported a more than acceptable ischemic stroke prevention. The major bleeding rates were also acceptably low and comparable to each other in the PMSSs of dabigatran (J-dabigatran), rivaroxaban (XAPASS), and edoxaban (ETNA-AF-Japan). However, the incidence in PMSS of apixaban (STANDARD) was more than double the others. This finding appeared to contradict th...
Source: European Journal of Clinical Pharmacology - March 14, 2023 Category: Drugs & Pharmacology Source Type: research

NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
Phase 1 safety study of NTS-104 is initiated in healthy volunteers Compound is being developed for stroke and other Central Nervous System (CNS) injuries ATLANTA, June 1, 2023 -- (Healthcare Sales & Marketing Network) -- NeuroTrauma Sciences, LLC (N... Biopharmaceuticals, Neurology, Drug Delivery NeuroTrauma Sciences, neurosteroid prodrug, stroke
Source: HSMN NewsFeed - June 1, 2023 Category: Pharmaceuticals Source Type: news

Any defence of sugar is pure confection | Aseem Malhotra
More and more people are challenging the food industry's PR machine. The evidence shows that sugar, not fat, is the enemyThe public health minister, Anna Soubry, has commented that the poor are more likely to be obese. It is well known that social status is linked to health, but her comments were also motivated by a mentality that victimises the most vulnerable. She should really be directing her criticism at the food industry. There is no doubt that an oversupply of cheap junk food fuelled by unregulated and irresponsible marketing limits our ability to make healthy choices. But there is an equally important question that...
Source: Guardian Unlimited Science - January 24, 2013 Category: Science Authors: Aseem Malhotra Tags: Comment Food & drink industry Obesity Health guardian.co.uk Health policy Society UK news Life and style Business Science Comment is free Source Type: news

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 2013
Presentation of neurological data confirms patients in the device group had fewer, smaller strokes that were less likely to originate from blood clots passing through the PFO ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc... Devices, Interventional CardiologySt. Jude Medical, patent foramen ovale, AMPLATZER, AMPLATZER PFO Occluder
Source: HSMN NewsFeed - February 8, 2013 Category: Pharmaceuticals Source Type: news

Kevin M. Smith Appointed to Zynex Board of Directors
LONE TREE, CO--(Healthcare Sales & Marketing Network) - Zynex, Inc. (OTCQB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the appointme... Devices, Neurology, PersonnelZynex, electrotherapy
Source: HSMN NewsFeed - April 30, 2013 Category: Pharmaceuticals Source Type: news

The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
Abstract The new anticoagulants (NOACs) tested for prevention or treatment of venous thromboembolism (VTE), stroke prevention in atrial fibrillation (AF), and acute coronary syndromes (ACS) differ in bioavailability, metabolism, route of excretion and interaction with other drugs, but have remarkably similar pharmacokinetics, with very similar half lives. However the choice of dosing regimens in different clinical conditions has been different for the various NOACs, and has been established on the basis of widely different considerations, including the clinical setting (venous versus arterial thrombosis), the indi...
Source: Vascular Pharmacology - July 18, 2013 Category: Drugs & Pharmacology Authors: Renda G, De Caterina R Tags: Vascul Pharmacol Source Type: research

FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.
Source: Reuters: Health - July 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news